Replies to post #127 on Equity Field Notes from temporal sources

[DanWebzster]

CRBP is a high risk play on its fast track synthetic cannabinoid chronic inflammation treatment.

The lead indication has orphan status for systemic sclerosis (~ 90,00 patients)

12-month data for this indication will be read out 5/18. Full Ph3 data is not expected until 2020.

The compound is also in Ph2 in: 1) dermatomyositis 2) cystic fibrosis.

Cash will provide a runway into 2019. CRBP will likely take advantage of any positive data to raise capital.

The cannabinoids have been shown repeatedly to work as part of the entourage effect. I believe single a synthetic cannabinoid will always be worth less than a natural spectrum of cannabinoids.

This stock is likely a scam.